A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women

    loading  Checking for direct PDF access through Ovid



To compare two enoxaparin dosing strategies at achieving prophylactic anti-Xa levels in women with a body mass index (BMI) ≥ 35 (kg m-2) postcesarean delivery.


Women with BMI ≥ 35 were randomized to receive prophylactic enoxaparin at a fixed dose of 40 mg daily or weight-based dosing of 0.5 mg kg-1 twice daily. The primary outcome was the proportion of subjects with peak anti-Xa levels in the prophylactic range of 0.2 to 0.6 IU ml-1.


From August 2013 through February 2014, 84 demographically similar women completed the protocol. In the weightbased group, 88% (37/42) of the women reached prophylactic anti-Xa levels versus 14% (6/42) in the fixed dose group (odds ratio 44.4, 95% confidence interval 12.44, 158.48, P < 0.001). No anti-Xa level exceeded 0.48 IU ml-1. There were no venous thromboembolic or bleeding events requiring reoperation or transfusion in either group.


Compared with fixed dosing daily, weight-based dosing twice daily more effectively achieved prophylactic anti-Xa levels without reaching the therapeutic range.

Related Topics

    loading  Loading Related Articles